Chapter 7: Lung Cancer

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Chapter 7: Lung Cancer"

Transcription

1 Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin / Etoposide... 2 Poor PS... 3 Carboplatin... 3 Etoposide... 3 Second Line Chemotherapy... 4 Etoposide... 4 Carboplatin... 4 VAC... 5 Topotecan... 5 Non-Small Cell Lung Cancer... 6 Adjuvant... 6 Cisplatin/Vinorelbine... 6 Carboplatin/Vinorelbine... 7 Carboplatin/Vinorelbine (split dose)... 8 Locally advanced... 9 Concurrent Chemo/Radiotherapy Cisplatin/Vinorelbine Intravenous... 9 Advanced Cisplatin / Pemetrexed Cisplatin/Vinorelbine Carboplatin/Gemicitabine Carboplatin/Vinorelbine Vinorelbine Gemcitabine Gefitinib (Iressa ) Erlotinib (Tarceva ) Maintenance Pemetrexed Second line Chemotherapy Docetaxel Erlotinib (Tarceva ) *Crizotinib *Pemetrexed Mesothelioma Cisplatin / Pemetrexed Carboplatin / Pemetrexed Issue Date: July 2014 Page 1 of 19 Issue No:

2 Small Cell Good PS + Limited stage Cisplatin/etoposide Cisplatin/etoposide Day 1 Cisplatin 70mg/m 2 IV infusion over 90 minutes Day 1 Etoposide 120mg/m 2 IV infusion over 60 minutes Day 2 Etoposide 240mg/m 2 Orally, in 2 divided doses Day 3 Etoposide 240mg/m 2 Orally, in 2 divided doses NB see cisplatin hydration recommendations Chapter 1 Laboratory investigations indicated Calculate creatinine clearance prior to each cycle and administer cisplatin according to guidelines Concurrent chemotherapy + XRT Cisplatin + etoposide as above with XRT commencing with cycle 2 Good / Intermediate PS Carboplatin / Etoposide Carboplatin/etoposide 4 to 6 cycles Day 1 Carboplatin AUC 5 IV infusion over 60 minutes Day 1 Etoposide phosphate 100mg/m 2 IV infusion over 15 minutes Day 2 Etoposide 200mg/m 2 Orally, in 2 divided doses Day 3 Etoposide 200mg/m 2 Orally, in 2 divided doses For patients unable to swallow oral etoposide capsules, daily intravenous etoposide phosphate can be administered (see separate electronic prescribing regimen) Issue Date: July 2014 Page 2 of 19 Issue No:

3 indicated Calculate or measure creatinine clearance prior to first cycle and before subsequent cycles if Poor PS Many poor PS patients will be too ill potentially to benefit from chemotherapy and symptomatic care will be the most appropriate option. For those judged to be fit enough the following may be considered: Carboplatin Carboplatin Day 1 Carboplatin AUC 4 to 5 IV infusion over 60 minutes Calculate or measure creatinine clearance prior to first cycle and before subsequent cycles if Etoposide Etoposide Upto 6 cycles Days 1 to 10 Etoposide 50mg BD Orally, twice a day for 10 days can be reduced to 7 days where indicated Calculate or measure creatinine clearance prior to first cycle and before subsequent cycles if Issue Date: July 2014 Page 3 of 19 Issue No:

4 Second Line Chemotherapy Etoposide Etoposide Upto 6 cycles Days 1 to 10 Etoposide 50mg BD Orally, twice a day for 10 days can be reduced to 7 days where indicated FBC prior to each cycle Normal FBC limits for administration apply Carboplatin Carboplatin Day 1 Carboplatin AUC 5 to 6 IV infusion over 60 minutes Calculate or measure creatinine clearance prior to first cycle and before subsequent cycles if FBC prior to each cycle Normal FBC limits for administration apply Issue Date: July 2014 Page 4 of 19 Issue No:

5 VAC VAC 4 to 6 cycles Day 1 Cyclophosphamide 750mg/m 2 IV bolus Day 1 Doxorubicin 50mg/m 2 IV bolus Day 1 Vincristine 1.4mg/m minutes (maximum dose 2mg) FBC prior to each cycle Normal FBC limits for administration apply Topotecan Topotecan Days 1 to 5 Topotecan 2.3mg/m 2 OD Orally, daily for 5 days Criteria PS 0-2 Cr Cl > 40ml/min CA125 prior to each cycle FBC prior to each dose Normal FBC limits for administration apply Issue Date: July 2014 Page 5 of 19 Issue No:

6 Non-Small Cell Lung Cancer Adjuvant Criteria Stage 1-3 completely resected PS 0-1 Cisplatin/Vinorelbine Cisplatin/Vinorelbine Intravenous 3 cycles Day 1 Cisplatin 80mg/m 2 IV infusion over 90 minutes Day 1 Vinorelbine 25mg/m Day 8 Vinorelbine 25mg/m OR Cisplatin/Vinorelbine Oral 3 cycles Day 1 Cisplatin 80mg/m 2 IV infusion over 90 minutes Day 1 Vinorelbine 60mg/m 2 Orally, single dose (maximum dose 120mg) Day 8 Vinorelbine 60mg/m 2 Orally, single dose (maximum dose 120mg) NB see cisplatin hydration recommendations Chapter 1 Laboratory investigations indicated Calculate creatinine clearance prior to each cycle and administer cisplatin according to guidelines Issue Date: July 2014 Page 6 of 19 Issue No:

7 Carboplatin/Vinorelbine Carboplatin/Vinorelbine Intravenous 3 cycles Day 1 Carboplatin AUC 5 IV infusion over 60 minutes Day 1 Vinorelbine 25mg/m Day 8 Vinorelbine 25mg/m OR Carboplatin/Vinorelbine Oral 3 cycles Day 1 Carboplatin AUC 5 IV infusion over 60 minutes Day 1 Vinorelbine 60mg/m 2 Orally, single dose (maximum dose 120mg) Day 8 Vinorelbine 60mg/m 2 Orally, single dose (maximum dose 120mg) Cycle length can be increased to 28 days if prolonged thrombocytopenia. indicated. Calculate or measure creatinine clearance prior to first cycle and before subsequent cycles if Issue Date: July 2014 Page 7 of 19 Issue No:

8 Carboplatin/Vinorelbine (split dose) Carboplatin/Vinorelbine Intravenous 3 cycles Day 1 Carboplatin AUC 2.5 IV infusion over 60 minutes Day 1 Vinorelbine 25mg/m Day 8 Carboplatin AUC 2.5 IV infusion over 60 minutes Day 8 Vinorelbine 25mg/m OR Carboplatin/Vinorelbine Oral 3 cycles Day 1 Carboplatin AUC 5 IV infusion over 60 minutes Day 1 Vinorelbine 60mg/m 2 Orally, single dose (maximum dose 120mg) Day 8 Carboplatin AUC 2.5 IV infusion over 60 minutes Day 8 Vinorelbine 60mg/m 2 Orally, single dose (maximum dose 120mg) Ciprofloxacin prophylaxis 500mg BD days 9 to 20 Cycle length can be increased to 28 days if prolonged thrombocytopenia. indicated Calculate or measure creatinine clearance prior to first cycle and before subsequent cycles if FBC prior to each cycle Normal FBC limits for administration apply Issue Date: July 2014 Page 8 of 19 Issue No:

9 Locally advanced Concurrent Chemo/Radiotherapy Cisplatin/Vinorelbine Intravenous Cisplatin/Vinorelbine Intravenous and concurrent radiotherapy One course only 4 weeks Fractions 1 to 4 Cisplatin 20mg/m 2 daily IV infusion over 60 minutes, daily Fraction 1 Vinorelbine 15mg/m minutes Fraction 6 Vinorelbine 15mg/m minutes Fraction 15 Vinorelbine 15mg/m minutes Fractions 16 to 19 Cisplatin 20mg/m 2 daily IV infusion over 60 minutes, daily Fraction 20 Vinorelbine 15mg/m minutes Note: these are chemotherapy treatments associated with fractions of radiotherapy, and therefore treatment should ideally commence on a Monday. If it commences on a different day of the week then consider the dates carefully when prescribing. Followed at 4-6 weeks by: Cisplatin/Vinorelbine Intravenous 2 cycles Day 1 Cisplatin 80mg/m 2 IV infusion over 90 minutes Day 1 Vinorelbine 25mg/m Day 8 Vinorelbine 25mg/m NB see cisplatin hydration recommendations Chapter 1 Laboratory investigations indicated Calculate creatinine clearance prior to each cycle and administer cisplatin according to guidelines Issue Date: July 2014 Page 9 of 19 Issue No:

10 Advanced Cisplatin / Pemetrexed Cisplatin/Pemetrexed Dexamethasone 4mg BD Orally for 3 days, commencing 24 hours prior to pemetrexed Day 1 Pemetrexed 500mg/m 2 IV infusion over 10 minutes Day 1 Cisplatin 75mg/m 2 IV infusion over 90 minutes NB see cisplatin hydration recommendations Chapter 1 Vitamin B12 injection IM 1 week prior to start + every 9 weeks until completion Folic acid 400micrograms daily oral during treatment, and for at least 3 weeks post treatment Stop all NSAIDS during chemotherapy Criteria: Non-squamous carcinomas PS 0-1 Cisplatin/Vinorelbine Cisplatin/Vinorelbine Intravenous Day 1 Cisplatin 80mg/m 2 IV infusion over 90 minutes Day 1 Vinorelbine 25mg/m Day 8 Vinorelbine 25mg/m Issue Date: July 2014 Page 10 of 19 Issue No:

11 OR Cisplatin/Vinorelbine Oral Day 1 Cisplatin 80mg/m 2 IV infusion over 90 minutes Day 1 Vinorelbine 60mg/m 2 Orally, single dose (maximum dose 120mg) Day 8 Vinorelbine 60mg/m 2 Orally, single dose (maximum dose 120mg) NB see cisplatin hydration recommendations see Chapter 1 Laboratory investigations indicated Calculate creatinine clearance prior to each cycle and administer cisplatin according to guidelines Carboplatin/Gemicitabine Carboplatin/Gemcitabine Day 1 Carboplatin AUC 5 IV infusion over 60 minutes Day 1 Gemcitabine 1250mg/m 2 IV infusion over 30 minutes Day 8 Gemcitabine 1250mg/m 2 IV infusion over 30 minutes Cycle interval can be increased to 28 days if indicated NB: transaminases may rise during treatment Calculate or measure creatinine clearance prior to first cycle and before subsequent cycles if Issue Date: July 2014 Page 11 of 19 Issue No:

12 Carboplatin/Vinorelbine Carboplatin/Vinorelbine Intravenous Day 1 Carboplatin AUC 4 to 5 IV infusion over 60 minutes Day 1 Vinorelbine 25mg/m Day 8 Vinorelbine 25mg/m OR Carboplatin/Vinorelbine Oral Day 1 Carboplatin AUC 4 to 5 IV infusion over 60 minutes Day 1 Vinorelbine 60mg/m 2 Orally, single dose (maximum dose 120mg) Day 8 Vinorelbine 60mg/m 2 Orally, single dose (maximum dose 120mg) Cycle length can be increased to 28 days if indicated Calculate or measure creatinine clearance prior to first cycle and before subsequent cycles if Vinorelbine Vinorelbine Intravenous Day 1 Vinorelbine 25 to 30mg/m Day 8 Vinorelbine 25 to 30mg/m OR Issue Date: July 2014 Page 12 of 19 Issue No:

13 Vinorelbine Oral 2 Orally, single dose (maximum doses 120mg Day 1 Vinorelbine 60 to 80mg/m and 160mg ie capped at 2m 2 ) 2 Orally, single dose (maximum doses 120mg Day 8 Vinorelbine 60 to 80mg/m and 160mg ie capped at 2m 2 ) Criteria: No prior chemotherapy PS 0-2 FBC prior to each cycle Normal FBC limits for administration apply Gemcitabine Gemcitabine Every 28 Days 6 cycles Day 1 Gemcitabine 1000mg/m 2 IV infusion over 30 minutes Day 8 Gemcitabine 1000mg/m 2 IV infusion over 30 minutes Day 15 Gemcitabine 1000mg/m 2 IV infusion over 30 minutes Day 15 can be omitted in patients with poorer PS or thrombocytopenia indicated NB: transaminases may rise during treatment Issue Date: July 2014 Page 13 of 19 Issue No:

14 Gefitinib (Iressa ) Gefitinib Continuous Until disease progression Daily Gefitinib 250mg daily Orally, daily Criteria Locally advanced / metastatic NSCLC, first line therapy EGFR mutation positive Erlotinib (Tarceva ) Erlotinib Continuous Until disease progression Daily Erlotinib 150mg daily Orally, daily Criteria EGFR mutation positive First line FBC prior to each cycle Normal FBC limits for administration apply Issue Date: July 2014 Page 14 of 19 Issue No:

15 Maintenance Pemetrexed Maintenance pemetrexed is available through the normal funding mechanism for patients who fulfil the criteria set out by NICE and who did not receive pemetrexed as part of first line therapy. For those patients who received pemetrexed as part of first line therapy and who fulfil the criteria funding is available via the CDF Pemetrexed maintenance Until disease progression Dexamethasone 4mg BD Orally for 3 days, commencing 24 hours prior to docetaxel Day 1 Pemetrexed 500mg/m 2 IV infusion over 10 minutes Vitamin B12 injection IM 1 week prior to start + every 9 weeks until completion Folic acid 400 micrograms daily oral during treatment, and for at least 3 weeks post treatment Stop all NSAIDS during chemotherapy Criteria: Non-squamous carcinomas PS 0-1 CR/PR/SD following first line chemotherapy First line chemotherapy with Platinum + vinorelbine/paclitaxel/gemcitabine/docetaxel *NB available via the Cancer Drugs fund CDF Criteria (as at 14 May 2014) The maintenance treatment of advanced non-squamous non-small cell lung cancer where all the following criteria are met: 1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. Non-squamous non-small cell lung cancer 3. As maintenance therapy following 1 st line chemotherapy with cisplatin and pemetrexed not progressing after of such chemotherapy 4. PS 0 or 1 at time to commence maintenance pemetrexed Note: the evidence for the use of maintenance pemetrexed following induction chemotherapy with the combination of pemetrexed and carboplatin has not been established and is therefore not approved. Issue Date: July 2014 Page 15 of 19 Issue No:

16 Second line Chemotherapy Docetaxel Docetaxel Dexamethasone 8mg BD Orally for 3 days, commencing 24 hours before docetaxel Day 1 Docetaxel 75mg/m 2 IV infusion over 60 minutes Criteria PS 0-1 Previous response or stable disease to platinum based chemotherapy Progression free interval following platinum based chemotherapy > 6m FBC prior to each cycle Normal FBC limits for administration apply Erlotinib (Tarceva ) Erlotinib Continuous Until disease progression Daily Erlotinib 150mg daily Orally, daily Criteria Progression following chemotherapy for advanced disease Fit to receive docetaxel as second line therapy No prior anti EGFR therapy Issue Date: July 2014 Page 16 of 19 Issue No:

17 *Crizotinib Crizotinib Continuous Until disease progression Daily Crizotinib 250mg BD Orally, twice daily Dose reduction is to 200mg BD *NB available via the Cancer Drugs fund CDF Criteria (as at 14 May 2014) The treatment of ALK +ve advanced or metastatic non-small cell lung cancer where all the following criteria are met: 1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. ALK +ve advanced or metastatic non-small cell lung cancer 3. 2 nd or subsequent line treatment post 1 st line combination chemotherapy Issue Date: July 2014 Page 17 of 19 Issue No:

18 *Pemetrexed Pemetrexed single agent Until disease progression Dexamethasone 4mg BD Orally for 3 days, commencing 24 hours before pemetrexed Day 1 Pemetrexed 500mg/m 2 IV infusion over 10 minutes Vitamin B12 1mg injection IM 1 week prior to start + every 9 weeks until completion Folic acid 400micrograms daily oral during treatment, and for at least 3 weeks post treatment Stop all NSAIDS during chemotherapy *NB available via the Cancer Drugs fund CDF Criteria (as at 14 May 2014) The second line treatment of advanced non-squamous non-small cell lung cancer where all the following criteria are met: 1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. Advanced or metastatic non-squamous non-small cell lung cancer 3. Used as 2 nd line treatment 4. No previous pemetrexed treatment Issue Date: July 2014 Page 18 of 19 Issue No:

19 Mesothelioma Cisplatin / Pemetrexed Cisplatin/Pemetrexed Upto 6 cycles Dexamethasone 4mg BD Orally for 5 days, commencing 24 hours before pemetrexed Day 1 Pemetrexed 500mg/m 2 IV infusion over 10 minutes Day 1 Cisplatin 75mg/m 2 IV infusion over 90 minutes NB see cisplatin hydration recommendations in chapter one Vitamin B12 injection IM 1 week prior to start + every 9 weeks until completion Folic acid 400micrograms daily oral during treatment and for at least 3 weeks post treatment Stop all NSAIDS during chemotherapy Carboplatin / Pemetrexed Carboplatin/Pemetrexed Upto 6 cycles Dexamethasone 4mg BD Orally for 5 days, commencing 24 hours before pemetrexed Day 1 Pemetrexed 500mg/m 2 IV infusion over 10 minutes Day 1 Carboplatin AUC 4 to 5 IV infusion over 60 minutes Vitamin B12 injection IM 1 week prior to start + every 9 weeks until completion Folic acid 400micrograms daily oral during treatment Stop all NSAIDS during chemotherapy Issue Date: July 2014 Page 19 of 19 Issue No:

Network Chemotherapy Regimens

Network Chemotherapy Regimens Network Chemotherapy Regimens Lung Cancer Notes from the editor Thames Valley Cancer Network These protocols are available on the Network website www.tvcn.org.uk. Any correspondence about the protocols

More information

SYSTEMIC THERAPY FOR STAGE IV NON-SMALL CELL LUNG CANCER: AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE UPDATE

SYSTEMIC THERAPY FOR STAGE IV NON-SMALL CELL LUNG CANCER: AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE UPDATE Which patients with stage IV NSCLC should be treated with chemotherapy? NSCLC with nonsquamous cell carcinoma, negative or unknown EGFR-sensitizing mutation and ALK gene rearrangement status, and PS 0-1

More information

Thames Valley Chemotherapy Regimens

Thames Valley Chemotherapy Regimens Chemotherapy Regimens Lung Cancer Notes from the editor These regimens are available on the Network website www.tvcn.org.uk. Any correspondence about the regimens should be addressed to: Sally Coutts,

More information

Schedule: Drug Dose iv/infusion/oral q Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8

Schedule: Drug Dose iv/infusion/oral q Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8 Carboplatin/Gemcitabine Lung Cancer (non-small cell) - Advanced Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8 Cycle frequency: Every three weeks Total

More information

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

Lung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC) Indication: NICE TA181 First line treatment option in advanced or metastatic non-squamous NSCLC (histology confirmed as adenocarcinoma or large cell carcinoma) Performance status 0-1 Regimen details: Pemetrexed

More information

POLICY A. INDICATIONS

POLICY A. INDICATIONS Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT

More information

Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist

Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the

More information

About chemotherapy for lung cancer

About chemotherapy for lung cancer About chemotherapy for lung cancer This information is about chemotherapy for lung cancer. There are sections on What is chemotherapy? Chemotherapy for small cell lung cancer Chemotherapy for non-small

More information

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015

More information

BREAST CANCER - METASTATIC & LOCALLY ADVANCED CHEMOTHERAPY REGIMENS Capecitabine. Capecitabine + Docetaxel. Capecitabine + Vinorelbine

BREAST CANCER - METASTATIC & LOCALLY ADVANCED CHEMOTHERAPY REGIMENS Capecitabine. Capecitabine + Docetaxel. Capecitabine + Vinorelbine Capecitabine Capecitabine 1000-1250mg/m 2 oral TWICE daily for 14 days Until disease progression Capecitabine + Docetaxel Capecitabine 750-1000mg/m 2 oral TWICE daily for 14 days Up to 6 cycles Capecitabine

More information

Adjuvant Chemotherapy 1. Vinorelbine-25/Cisplatin-80 (chemo alone) CTIS 1722 4 2. Gemcitabine-1250/Carboplatin-5AUC CTIS 1601 5

Adjuvant Chemotherapy 1. Vinorelbine-25/Cisplatin-80 (chemo alone) CTIS 1722 4 2. Gemcitabine-1250/Carboplatin-5AUC CTIS 1601 5 LUNG CANCER Section by: Dr Conrad Lewanski, Dr Danielle Power, Dr Tom Newsom-Davis Version; Lung Cancer Regimens v4.3 NWLCN 20Feb12 Section last reviewed: 1 st July 2011 Section last corrected: 20 th February

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS

More information

London Cancer. Mesothelioma Lung Protocols

London Cancer. Mesothelioma Lung Protocols London Cancer Mesothelioma Lung Protocols Version 0.9 Contents 1. Staging... 3 2. Mesothelioma Summary of Chemotherapy Protocols... 4 3. Mesothelioma Chemotherapy Protocols... 7 3.1. Pemetrexed (Alimta

More information

SAKK Lung Cancer Group. Current activities and future projects

SAKK Lung Cancer Group. Current activities and future projects SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation

More information

3.0 With final Comments for presentation at Sub Group Meeting 24. 24.11.10

3.0 With final Comments for presentation at Sub Group Meeting 24. 24.11.10 Guideline for the Treatment of Lung Cancer Version History 2.0 Endorsed by the Governance Committee as treatment of lung cancer 27.07.09 with radiotherapy and chemotherapy. 2.1 Re-written to include the

More information

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

More information

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

Summary of treatment benefits

Summary of treatment benefits Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell

More information

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007 Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.

More information

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10 Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage

More information

Systemic Therapy for Stage IV Non-Small Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Systemic Therapy for Stage IV Non-Small Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Systemic Therapy for Stage IV Non-Small Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Introduction The purpose of this guideline update is to revise the 2011

More information

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

Summary ID# 13095. Clinical Study Summary: Study H3E-EW-B012

Summary ID# 13095. Clinical Study Summary: Study H3E-EW-B012 Page 1 Summary ID# 13095 Clinical Study Summary: Study H3E-EW-B012 First-line Treatment of Non-Small Cell Lung Cancer under Routine Conditions: Observational Study on Overall Survival Date summary electronically

More information

Out-Patient Chemotherapy for Lung Cancer

Out-Patient Chemotherapy for Lung Cancer Lung Cancer Out-Patient Chemotherapy for Lung Cancer Principles and practice JMAJ 46(12): 542 546, 2003 Shuichi YONEDA Director, Department of Pulmonary Medicine, Saitama Cancer Center Abstract: Recent

More information

REPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group

REPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group 1 REPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group 10 MESSAGE HIGHLIGHTS Early stage non-small cell lung cancer

More information

Chemotherapy for lung cancer

Chemotherapy for lung cancer This information is an extract from the booklet Understanding lung cancer. You may find the full booklet helpful. We can send you a free copy see page 8. Contents Chemoradiation Small cell lung cancer

More information

Guidelines for the Use of Anti-Emetics with Chemotherapy

Guidelines for the Use of Anti-Emetics with Chemotherapy Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting

More information

West of Scotland Cancer Network Chemotherapy Protocol. Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021)

West of Scotland Cancer Network Chemotherapy Protocol. Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021) West of Scotland Cancer Network Chemotherapy Protocol Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021) Indication Palliative chemotherapy for malignant mesothelioma of the pleura Eligibility

More information

Activity of pemetrexed in thoracic malignancies

Activity of pemetrexed in thoracic malignancies Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is

More information

Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue)

Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Professeur Jean Trédaniel Unité de cancérologie thoracique Hôpital Saint-Louis Comparison of Four

More information

Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer

Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer Background: A non-anthracycline based regimen for high-risk, HER 2 positive breast cancer in the adjuvant setting (BCIRG 006). Patient

More information

Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer

Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer 31 May 2012 Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer PHARMAC is seeking feedback on a proposal to: fund gefitinib (Iressa) as a first line treatment for patients with locally

More information

Management of Unresected Stage Ill Non-Small Cell Lung Cancer

Management of Unresected Stage Ill Non-Small Cell Lung Cancer Evidence-based Series 7-3 Version 2.2005 [TO BE UPDATED] A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Management of Unresected Stage Ill Non-Small Cell Lung

More information

Is there a positive effect of participation on a clinical trial for patients with advanced nonsmall cell lung cancer?

Is there a positive effect of participation on a clinical trial for patients with advanced nonsmall cell lung cancer? Original Article Is there a positive effect of participation on a clinical trial for patients with advanced nonsmall cell lung cancer? Rajappa S, Gundeti S, Uppalapati S, Jiwatani S, Abhyankar A, Pal C,

More information

LUNG CANCER TREATMENT REGIMENS (Part 1 of 7)

LUNG CANCER TREATMENT REGIMENS (Part 1 of 7) LUNG CANCER TREATMENT S (Part 1 of 7) Clinical Trials: The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration,

More information

Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology

More information

Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART

Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized

More information

Emerging Drug List GEFITINIB

Emerging Drug List GEFITINIB Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:

More information

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3

More information

A Randomized Placebo Controlled Study of Erlotinib (OSI-774, Tarceva

A Randomized Placebo Controlled Study of Erlotinib (OSI-774, Tarceva A Randomized Placebo Controlled Study of Erlotinib (OSI-774, Tarceva ) ) versus Placebo in Patients with Incurable Non-Small Cell Lung Cancer Who Have Failed Standard Therapy for Advanced or Metastatic

More information

Recruiting now. Could you help by joining this study?

Recruiting now. Could you help by joining this study? Non-Small Cell Lung Cancer Recruiting now AstraZeneca is looking for men and women with locally advanced or metastatic non-small cell lung cancer (NSCLC) to join ATLANTIC, a clinical study to help investigate

More information

Lung Cancer: More than meets the eye

Lung Cancer: More than meets the eye Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research

More information

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited

More information

REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) GSK1572932A (NON-SMALL CELL LUNG CANCER) - Executive Summary GSK1572932A (MAGE-A3): Key Metrics in NSCLC Markets

More information

Pharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain

Pharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenomic Approaches Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenetics & Pharmacogenomics Medicine tailored to the individual Genetic information, including the

More information

Oncological Treatment of Head & Neck Cancer

Oncological Treatment of Head & Neck Cancer Kent & Medway - Cancer Oncological Treatment of Head & Neck Cancer Pathway of Care Kent & Medway Cancer Collaborative Publication date April 2014 Expected review date April 2016 Version number 6 Version

More information

Lung Cancer Network Group. Lung Cancer Awareness Month November 2010

Lung Cancer Network Group. Lung Cancer Awareness Month November 2010 Lung Cancer Network Group Lung Cancer Awareness Month November 2010 Lung cancer is the leading cause of cancer related death in the Northern Ireland and the UK 1,2. Each year in Northern Ireland approximately

More information

Non-small cell lung cancer (NSCLC) is the most

Non-small cell lung cancer (NSCLC) is the most Vol 3 April 2011 Clinical Pharmacist 109 First-line treatment for non-small cell lung cancer is surgery; but many patients are not suitable and, for these patients, management may involve radiotherapy,

More information

WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,

WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, FACT SHEET BRANDED/GENERIC NAME: ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) ABRAXANE is an albumin-bound form of paclitaxel with a

More information

REPORT ASCO 1998 LOS ANGELES : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group

REPORT ASCO 1998 LOS ANGELES : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group REPORT ASCO 1998 LOS ANGELES : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group Educational session Treatment of stage III non-small cell lung cancer (NSCLC) in

More information

Systemic Therapy of Lung Cancer: Chemotherapy (Video Transcript)

Systemic Therapy of Lung Cancer: Chemotherapy (Video Transcript) Systemic Therapy of Lung Cancer: Chemotherapy (Video Transcript) To view the accompanying video of this transcript and to download a PDF of the physician's slide presentation, visit: http://www.uchospitals.edu/specialties/cancer/lung/video/index.html

More information

Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer in East tasia Chia-Chi (Josh) Lin, MD, PhD 林 家 齊 Director of Phase I Center, e Department of Oncology, National Taiwan University Hospital Clinical Associate Professor, Department

More information

YCN Lung NSSG YCN Radiotherapy & Chemotherapy Guidelines for Lung Cancer & Mesothelioma

YCN Lung NSSG YCN Radiotherapy & Chemotherapy Guidelines for Lung Cancer & Mesothelioma YCN Lung NSSG YCN Radiotherapy & Chemotherapy Guidelines for Lung Cancer & Mesothelioma *** VALID ON DATE OF PRINTING ONLY - all guidelines available at http://www.ycn.nhs.uk/ *** page 1 of 83 i Document

More information

National Clinical Trials Network Groups Update Fall 2014

National Clinical Trials Network Groups Update Fall 2014 National Clinical Trials Network Groups Update Fall 2014 Walter J Curran, Jr, MD An NRG Oncology Group Chair Executive Director Winship Cancer Institute of Emory University Atlanta, GA NCTN Groups Update

More information

non-small-cell lung cancer Quimioterapia adjuvante para câncer de pulmão não pequenas

non-small-cell lung cancer Quimioterapia adjuvante para câncer de pulmão não pequenas Adjuvant chemotherapy for non-small-cell lung cancer Quimioterapia adjuvante para câncer de pulmão não pequenas células Daniel B. Costa, MD, PhD, MMSc Division i i of Hematology/Oncology l Beth Israel

More information

2011 ATS International Conference May 13-18, 2011 Denver, Colorado CME POST-TEST QUESTIONAIRE

2011 ATS International Conference May 13-18, 2011 Denver, Colorado CME POST-TEST QUESTIONAIRE 2011 ATS International Conference May 13-18, 2011 Denver, Colorado CME POST-TEST QUESTIONAIRE Please fill your post-test answers in on this page and fax it back to the ATS Education Unit, ATTN: Elizabeth

More information

Cycle frequency: Every three weeks Total number of cycles: 3 or 4

Cycle frequency: Every three weeks Total number of cycles: 3 or 4 BEP 3-day (Bleomycin/Etoposide/Cisplatin) Germ cell tumours Bleomycin 30,000iu 200mls N. Saline/30mins Days 2, 8 & 15 Etoposide 165mg/m 2 1L N. Saline/1hr Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/4hrs

More information

Cetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient

Cetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)

More information

the standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009

the standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 Mesothelioma: The standard of care Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 take home messages PILC 2006 All patients should receive adequate palliation of dyspnea and pain before starting chemotherapy

More information

Stage I, II Non Small Cell Lung Cancer

Stage I, II Non Small Cell Lung Cancer Stage I, II Non Small Cell Lung Cancer Best Results T1 (less 3 cm) N0 80% 5 year survival No Role Adjuvant Chemotherapy Radiation Therapy Reduces Local Recurrence No Improvement in Survival 1 Staging Mediastinal

More information

NON-SMALL CELL LUNG CANCER STAGE IV

NON-SMALL CELL LUNG CANCER STAGE IV NON-SMALL CELL LUNG CANCER STAGE IV Effective Date: November, 2013 The recommendations contained in this guideline are a consensus of the Alberta Provincial Thoracic Tumour Team synthesis of currently

More information

Treatment Paradigm in NSCLC Treatment

Treatment Paradigm in NSCLC Treatment Treatment Paradigm in NSCLC Treatment Era of Targeted Therapy Aumkhae Sookprasert, MD Medicine Department, KKU Which factors taken to be account in NSCLC treatment? 1. Staging 2. ECOG performance status

More information

SEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS): PubMed 1966-3/16/2012 Cochrane Database of Systematic Reviews All years

SEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS): PubMed 1966-3/16/2012 Cochrane Database of Systematic Reviews All years Appendix A. Search Strategy for Systematic Reviews and Cost-Effectiveness Analyses (Search #1) TREATMENT OF METASTATIC NON-SMALL-CELL LUNG CANCER SEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS):

More information

cure toadvances in Lung Cancer A Patient s Guide

cure toadvances in Lung Cancer A Patient s Guide A Patient s Guide toadvances in Lung Cancer The Biology of Lung Cancer New Methods for Detection The Latest Treatment Options Questions to Ask Your Doctor Resources cure C ancer U pdates, R esearch & E

More information

Active centers: 2. Number of patients/subjects: Planned: 20 Randomized: Treated: 20 Evaluated: Efficacy: 13 Safety: 20

Active centers: 2. Number of patients/subjects: Planned: 20 Randomized: Treated: 20 Evaluated: Efficacy: 13 Safety: 20 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer

More information

Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC) Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC) Indication: In combination with docetaxel in locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma

More information

Non Hodgkins Lymphoma primary treatment

Non Hodgkins Lymphoma primary treatment Non Hodgkins Lymphoma primary treatment R-CHOP 21 R-CHOP 14 Primary chemotherapy for diffuse large B cell NHL. Treatment option for: * low-grade NHL with high-grade transformation or high risk features.

More information

CHEMOTHERAPY PROTOCOLS V10.1

CHEMOTHERAPY PROTOCOLS V10.1 CHEMOTHERAPY PROTOCOLS V10.1 Issue Date: 10 th July 2014 Page 1 of 42 Filename: MCHACPROTO Issue No: 10.1 CCC Chemotherapy Protocols Haematological Malignancies... 3 Hodgkins disease...3 Non-Hodgkins Lymphoma...5

More information

NON-SMALL CELL LUNG CANCER

NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER Executive Summary In 2012, an estimated 1.8 million people were diagnosed with lung cancer resulting in 1.6 million deaths (http://globocan.iarc.fr/pages/fact_sheets_cancer.aspx).

More information

Hydration, IV Infusions, Injections and Vaccine Charge Process

Hydration, IV Infusions, Injections and Vaccine Charge Process There are a number of items to be considered when billing for the Nursing service to perform drug therapy, the charge process is divided into three specific groups of codes and processes. 1. Hydration

More information

British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015

British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015 0116 250 2811 dawn.mckinley@uhl-tr.nhs.uk www.btog.org @BTOGORG British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015 BTOG s Aim BTOG is the multi-disciplinary group for professionals

More information

New Trends & Current Research in the Treatment of Lung Cancer, Pt. II

New Trends & Current Research in the Treatment of Lung Cancer, Pt. II New Trends & Current esearch in the Treatment of Lung Cancer, Pt. II Howard (Jack) West, MD President & CEO, GACE Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA Cancer

More information

REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM

REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM Valerie Van Damme, Isabelle Wauters, Johan Vansteenkiste Univ. Hospital Leuven and Leuven Lung Cancer Group Introduction Perspectives in Lung Cancer (PILC)

More information

Controversies in Management of. Inoperable NSCLC. Inoperable NSCLC. Introduction:

Controversies in Management of. Inoperable NSCLC. Inoperable NSCLC. Introduction: Inoperable NSCLC Controversies in Management of Inoperable NSCLC Introduction: It is difficult to overemphasize the magnitude of lung cancer as Public Health Problem in our society. - In US, Lung cancer

More information

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in

More information

Cycle frequency: Every three weeks Total number of cycles: 6

Cycle frequency: Every three weeks Total number of cycles: 6 Carboplatin/Paclitaxel Ovarian Cancer Adjuvant, Advanced Paclitaxel 175mg/m 2 500mls 5% dex/3hrs Day 1 Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Anti-emetic group - Moderately high Paclitaxel given first

More information

CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER. Walter Stadler, MD University of Chicago

CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER. Walter Stadler, MD University of Chicago CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER Walter Stadler, MD University of Chicago Chemotherapy Doctor Terms Drugs used to treat cancer Will attack cancer no matter where it is located

More information

targeted therapy a guide for the patient

targeted therapy a guide for the patient targeted therapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2-3 Gene changes... 4-5 Testing... 7-8 Targeted therapy... 9-11 Drugs Targeting EGFR... 12 Drugs Targeting

More information

Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015

Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015 Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015 Advanced Refractory Solid Tumors or Lymphomas ECOG-ACRIN EAY131 (NCI CIRB) Targeted Therapy Directed by Genetic Testing in Treating

More information

Spread the Word, Once and for All. The Lung Cancer Prevention & Detection Kit

Spread the Word, Once and for All. The Lung Cancer Prevention & Detection Kit Spread the Word, Once and for All The Lung Cancer Prevention & Detection Kit About Spread the Word, Once and for All The NFCR Lung Cancer Prevention and Detection Kit Lung cancer is the leading killer

More information

Small Cell Lung Cancer

Small Cell Lung Cancer Small Cell Lung Cancer Lung Practice Guideline Dr. Brian Dingle MSc, MD, FRCPC Approval Date: April 2007 Revised: November 2008 This guideline is a statement of consensus of the Thoracic Disease Site Team

More information

MAINTENANCE CHEMOTHERAPY

MAINTENANCE CHEMOTHERAPY 1 MAINTENANCE CHEMOTHERAPY FOR ADVANCED NSCLC Dr.M.V.Nagarjuna OBJECTIVES OF THIS SEMINAR 1. Definitions 2. Switch maintenance 3. Continuation Maintenance 4. Immunotherapy as maintenance 5. Conclusions

More information

Cytotoxic Therapy in Metastatic Breast Cancer

Cytotoxic Therapy in Metastatic Breast Cancer Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Version 2002: von Minckwitz Versions

More information

Lung Cancer and Mesothelioma

Lung Cancer and Mesothelioma Lung Cancer and Mesothelioma Robert Kratzke, M.D. John C. Skoglund Professor of Lung Cancer Research Section of Heme/Onc/Transplant Department of Medicine University of Minnesota Medical School Malignant

More information

Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group

Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage

More information

NOTTINGHAM UNIVERSITY NHS TRUST BREAST INSTITUTE GUIDELINE NEOADJUVANT CHEMOTHERAPY (NACT) FOR BREAST CANCER

NOTTINGHAM UNIVERSITY NHS TRUST BREAST INSTITUTE GUIDELINE NEOADJUVANT CHEMOTHERAPY (NACT) FOR BREAST CANCER NOTTINGHAM UNIVERSITY NHS TRUST BREAST INSTITUTE GUIDELINE NEOADJUVANT CHEMOTHERAPY (NACT) FOR BREAST CANCER Definitions: NACT is recommended initial treatment for inflammatory breast cancer and inoperable

More information

Update on Small Cell Lung Cancer

Update on Small Cell Lung Cancer Welcome to Master Class for Oncologists Session 3: 2:45 PM - 3:30 PM Washington, DC March 28, 2009 Small Cell Lung Cancer: Best Practices & Recent Advances Speaker: Bruce E. Johnson, MD Professor of Medicine,

More information

Lung cancer (non-small-cell)

Lung cancer (non-small-cell) Patient information from the BMJ Group Lung cancer (non-small-cell) It can be devastating to find out that you or someone close to you has lung cancer. You will have to make some important decisions about

More information

West of Scotland Cancer Network Systemic Anti-Cancer Therapy Protocol

West of Scotland Cancer Network Systemic Anti-Cancer Therapy Protocol West of Scotland Cancer Network Systemic Anti-Cancer Therapy Protocol FEC-DH in the adjuvant treatment of Breast Cancer (BRWOS- 031/1) Indication Adjuvant chemotherapy for HER2+ve Early Breast Cancer Eligibility

More information

DECISION AID. STAGE IV Non-Small Cell Lung Cancer (NSCLC) Second-Line Chemotherapy

DECISION AID. STAGE IV Non-Small Cell Lung Cancer (NSCLC) Second-Line Chemotherapy DECISION AID STAGE IV Non-Small Cell Lung Cancer (NSCLC) Second-Line Chemotherapy This is a DECISION AID for patients who have Stage IV non-small cell lung cancer (NSCLC), and are trying to decide whether

More information

Post-operative intrapleural chemotherapy for mesothelioma

Post-operative intrapleural chemotherapy for mesothelioma Post-operative intrapleural chemotherapy for mesothelioma Robert Kratzke, MD John Skoglund Chair for Lung Cancer Research Section of Heme-Onc-Transplant University of Minnesota Medical School Efficacy

More information

The Emperor s New Clothing

The Emperor s New Clothing Chemotherapy for Early Stage High-Risk Endometrial Cancer: Opposed Hal Hirte Medical Oncologist Juravinski Cancer Centre Hamilton, Ontario The Emperor s New Clothing The Emperor s New Chemotherapy Outline

More information

Ovarian, Fallopian Tube, and Peritoneal Cancer - Treatment Options [1]

Ovarian, Fallopian Tube, and Peritoneal Cancer - Treatment Options [1] Home > Types of Cancer > Ovarian, Fallopian Tube, and Peritoneal Cancer > Ovarian, Fallopian Tube, and Peritoneal Cancer - Treatment Options PDF generated on September 2, 2016 from http://www.cancer.net/cancer-types/ovarian-fallopian-tube-andperitoneal-cancer/treatment-options

More information

Multidisciplinary discussion of: Early staged NSCLC

Multidisciplinary discussion of: Early staged NSCLC Multidisciplinary discussion of: Early staged NSCLC 2 different classes of patients Stage IIIA pt2pn2 Stage IIB pt3pn0 2 different classes of patients 50% 40% 30% 20% 10% 3y survival 50% 40% 30% 20% 10%

More information